[go: up one dir, main page]

PA8638701A1 - Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos - Google Patents

Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Info

Publication number
PA8638701A1
PA8638701A1 PA20058638701A PA8638701A PA8638701A1 PA 8638701 A1 PA8638701 A1 PA 8638701A1 PA 20058638701 A PA20058638701 A PA 20058638701A PA 8638701 A PA8638701 A PA 8638701A PA 8638701 A1 PA8638701 A1 PA 8638701A1
Authority
PA
Panama
Prior art keywords
derivatives
pirrol
oxindol
understanding
progesterone
Prior art date
Application number
PA20058638701A
Other languages
English (en)
Inventor
Michael Anthony Marella
Andrew Fensome
Casey Cameron Mccomas
Edward George Melenski
Jay Edward Wrobel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34993110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8638701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8638701A1 publication Critical patent/PA8638701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PROVEEN DERIVADOS DE PIRROL-OXINDOL UTILES COMO ANTAGONISTAS DEL RECEPTOR DE PROGESTERONA. SE DESCRIBEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS DERIVADOS, COMO ASI TAMBIEN EL USO DE LAS MISMAS EN ANTICONCEPCION Y AFECCIONES RELACIONADAS CON HORMONAS.
PA20058638701A 2004-08-09 2005-07-06 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos PA8638701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59990004P 2004-08-09 2004-08-09

Publications (1)

Publication Number Publication Date
PA8638701A1 true PA8638701A1 (es) 2006-06-02

Family

ID=34993110

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058638701A PA8638701A1 (es) 2004-08-09 2005-07-06 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Country Status (20)

Country Link
US (1) US20060030615A1 (es)
EP (1) EP1778222A1 (es)
JP (1) JP2008509216A (es)
KR (1) KR20070039925A (es)
CN (1) CN101001625A (es)
AR (1) AR049708A1 (es)
AU (1) AU2005277879A1 (es)
BR (1) BRPI0514196A (es)
CA (1) CA2573310A1 (es)
EC (1) ECSP077236A (es)
GT (1) GT200500183A (es)
IL (1) IL180955A0 (es)
MX (1) MX2007001614A (es)
NO (1) NO20070723L (es)
PA (1) PA8638701A1 (es)
PE (1) PE20060555A1 (es)
RU (1) RU2007101304A (es)
TW (1) TW200605882A (es)
WO (1) WO2006023107A1 (es)
ZA (1) ZA200701156B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
MXPA06014579A (es) 2004-07-07 2007-03-01 Wyeth Corp Regimenes de progestina ciclicos y equipos.
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
ES2340518T3 (es) * 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
ES2340610T3 (es) * 2005-04-28 2010-06-07 Wyeth Llc Composiciones de tanaproget micronizado y procedimientos de preparacion de las mismas.
WO2007030153A2 (en) * 2005-04-28 2007-03-15 Wyeth Compositions containing micronized tanaproget
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070220A1 (es) 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
US20080051585A1 (en) * 2006-08-17 2008-02-28 Wyeth Process for the preparation of indolin-2-one derivatives useful as PR modulators
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
US20080312306A1 (en) * 2007-06-15 2008-12-18 Wyeth Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile
US20080319204A1 (en) * 2007-06-25 2008-12-25 Wyeth Process for the synthesis of progesterone receptor modulators
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (zh) 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6462032B1 (en) * 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
TW200605882A (en) 2006-02-16
US20060030615A1 (en) 2006-02-09
JP2008509216A (ja) 2008-03-27
GT200500183A (es) 2006-04-10
AR049708A1 (es) 2006-08-30
MX2007001614A (es) 2007-04-10
PE20060555A1 (es) 2006-06-26
CA2573310A1 (en) 2006-03-02
IL180955A0 (en) 2007-07-04
ECSP077236A (es) 2007-03-29
WO2006023107A1 (en) 2006-03-02
CN101001625A (zh) 2007-07-18
AU2005277879A1 (en) 2006-03-02
NO20070723L (no) 2007-05-07
ZA200701156B (en) 2008-08-27
RU2007101304A (ru) 2008-09-20
KR20070039925A (ko) 2007-04-13
EP1778222A1 (en) 2007-05-02
BRPI0514196A (pt) 2008-06-03

Similar Documents

Publication Publication Date Title
PA8638701A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PA8638801A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CR11017A (es) Anticuerpos anti-robo4 y sus usos
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
AR047928A1 (es) Derivados de tetrahidropiridoindol
ECSP088648A (es) Nuevos bencimidazoles 2-sustituidos como moduladores de receptor de androgeno selectivos (sarms)
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
UY32029A (es) "derivados de pirazolo -[5.1-b] - oxazol, su prepraración, composiciones farmacéuticas que los contienen y aplicaciones"
GT200500237A (es) Derivados de pirimidina
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
CL2009000245A1 (es) Compuestos derivados de heterociclil piridinilo, con actividad moduladora del receptor 5-ht6; composicion farmaceutica que los comprende y su uso para tratar la esquizofrenia, ansiedad, migrana, depresion, entre otros.
CO6390082A2 (es) Compuestos organicos
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CR10545A (es) Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
GT201000342A (es) Derivados de isozazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
DOP2011000304A (es) Nuevos derivados de compuestos de [3,2-c] pirazol esteroidal con actividad glucocorticoide
CL2011000405A1 (es) Compuestos derivados de n-sulfonamido pirazolil policiclico; inhibidores de la liberacion y sintesis de peptidos beta-amiloides y y-secretasa; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades alzheimer, parkinson, sindrome de down, entre otras.